These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15991291)

  • 1. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
    Lin TJ; Lin CL; Wang CS; Liu SO; Liao LY
    World J Gastroenterol; 2005 Jul; 11(25):3905-8. PubMed ID: 15991291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C.
    Sikorska K; Stalke P; Romanowski T; Rzepko R; Bielawski KP
    Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):377-84. PubMed ID: 23924495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.
    Erhardt A; Maschner-Olberg A; Mellenthin C; Kappert G; Adams O; Donner A; Willers R; Niederau C; Häussinger D
    J Hepatol; 2003 Mar; 38(3):335-42. PubMed ID: 12586300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prevalence of peripheral iron overload and the presence of HFE gene (H63D) mutation among the Korean patients with nonalcoholic fatty liver disease].
    Lee D; Jeong SH; Lee M; Cho YA; Kim JW; Park Y; Hwang JH; Kim NY; Lee DH
    Korean J Hepatol; 2007 Jun; 13(2):174-84. PubMed ID: 17585191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan.
    Mah YH; Kao JH; Liu CJ; Chen CL; Chen PJ; Lai MY; Chen DS
    Liver Int; 2005 Apr; 25(2):214-9. PubMed ID: 15780041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.
    Nelson JE; Brunt EM; Kowdley KV;
    Hepatology; 2012 Nov; 56(5):1730-40. PubMed ID: 22611049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Valenti L; Fracanzani AL; Bugianesi E; Dongiovanni P; Galmozzi E; Vanni E; Canavesi E; Lattuada E; Roviaro G; Marchesini G; Fargion S
    Gastroenterology; 2010 Mar; 138(3):905-12. PubMed ID: 19931264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload and HFE gene mutations in Czech patients with chronic liver diseases.
    Dostalikova-Cimburova M; Kratka K; Stransky J; Putova I; Cieslarova B; Horak J
    Dis Markers; 2012; 32(1):65-72. PubMed ID: 22297603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
    Toll A; Celis R; Ozalla MD; Bruguera M; Herrero C; Ercilla MG
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1201-6. PubMed ID: 17062032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epidemiologic study on the incidence and significance of HFE mutations in a Korean cohort with nonalcoholic fatty liver disease.
    Lee SH; Jeong SH; Lee D; Lee JH; Hwang SH; Cho YA; Park YS; Hwang JH; Kim JW; Kim N; Lee DH; Kang W
    J Clin Gastroenterol; 2010 Aug; 44(7):e154-61. PubMed ID: 20216079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heterozygosis H63D in patients with steatohepatitis and chronic hepatitis C].
    Pulvirenti D; Neri S; Bertino G; Cutuli N; Ignaccolo L; Misseri M; Tsami A; Caruso L
    Clin Ter; 2006; 157(6):485-8. PubMed ID: 17228846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia].
    Nie L; Ai XF; Zheng YZ; Li QH; Yang L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):223-8. PubMed ID: 19731820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
    Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.
    Bugianesi E; Manzini P; D'Antico S; Vanni E; Longo F; Leone N; Massarenti P; Piga A; Marchesini G; Rizzetto M
    Hepatology; 2004 Jan; 39(1):179-87. PubMed ID: 14752836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity.
    Chitturi S; Weltman M; Farrell GC; McDonald D; Kench J; Liddle C; Samarasinghe D; Lin R; Abeygunasekera S; George J
    Hepatology; 2002 Jul; 36(1):142-9. PubMed ID: 12085358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C.
    Lebray P; Zylberberg H; Hue S; Poulet B; Carnot F; Martin S; Chretien Y; Pol S; Caillat-Zuckman S; Bréchot C; Nalpas B
    J Viral Hepat; 2004 Mar; 11(2):175-82. PubMed ID: 14996353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis.
    Ladero JM; Ropero P; Ortega L; Taxonera C; González FA; López-Alonso G; Briceño O; Rodríguez-Agulló JL; González L; Villegas A; Díaz-Rubio M
    Rev Esp Enferm Dig; 2003 Dec; 95(12):829-36. PubMed ID: 14972004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations.
    Neri S; Pulvirenti D; Signorelli S; Ignaccolo L; Tsami A; Mauceri B; Misseri M; Interlandi D; Cutuli N; Castellino P
    Intern Med J; 2008 Apr; 38(4):254-8. PubMed ID: 17916170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open population screening study for HFE gene major mutations proves the low prevalence of C282Y mutation in Central Italy.
    Floreani A; Rosa Rizzotto E; Basso D; Navaglia F; Zaninotto M; Petridis I; DI Andrea O; Testa R; Marra M; Baldo V; Chiaramonte M
    Aliment Pharmacol Ther; 2007 Aug; 26(4):577-86. PubMed ID: 17661761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.